Siliq (brodalumab) Patient Assistance Program
Don’t let the high cost of brand IL-17 receptor antagonist disrupt your plaque psoriasis treatment. We help eligible patients access Siliq (brodalumab SC injection) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Siliq (brodalumab) is FDA-approved for treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or lost response to other systemic therapies. Anti-IL-17 receptor A (IL-17RA) monoclonal antibody — blocks IL-17RA subunit and multiple IL-17 family cytokines. REMS program due to suicidal ideation and behavior signal in early development.
- Without assistance, Siliq costs commonly run approximately $6,500–$8,500 per month.
- Through AffordMyPrescriptions, qualifying patients can access Siliq for a flat $69.95 per month.
- Other IL-17 pathway biologics for psoriasis: Cosentyx (secukinumab — IL-17A brand), Taltz (ixekizumab — IL-17A brand), Bimzelx (bimekizumab — IL-17A + IL-17F brand). IL-23 biologics: Tremfya (guselkumab), Skyrizi (risankizumab), Ilumya (tildrakizumab), Stelara (ustekinumab — IL-12/23). TNF inhibitors (many biosimilars available): Humira (adalimumab and biosimilars — 8+ biosimilars), Enbrel (etanercept and biosimilars — Erelzi, Eticovo), Remicade (infliximab and biosimilars — Inflectra, Renflexis, Avsola). Older systemics (all generic): methotrexate, cyclosporine, acitretin. Newer oral: Sotyktu (deucravacitinib — TYK2), Otezla (apremilast). Comprehensive dermatology assessment.
What is Siliq Prescription Assistance Program?
The Siliq Patient Assistance Program helps eligible patients access this IL-17 receptor antagonist at little or no cost when meeting income, insurance, and clinical criteria. Free to apply but requires detailed applications, dermatology coordination, REMS enrollment, and renewal.
At AffordMyPrescriptions, our Patient Advocates handle the entire Siliq PAP enrollment for a flat $69.95 per month — so you never face a gap in Siliq psoriasis therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Siliq enrollment — so you never face a gap in your plaque psoriasis treatment.
Pharmacy Price Comparison
- Without assistance, Siliq costs thousands per month. A Patient Assistance Program can offset costs if you qualify:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Adalimumab biosimilar (TNF alt) | ~$3,500/mo | TNF biosimilar much cheaper |
| Specialty pharmacy | ~$7,000/mo | Save substantially |
| Walgreens Specialty | ~$8,000/mo | Save substantially |
| CVS Specialty | ~$8,500/mo | Save substantially |
| 340B-eligible institution | ~$6,500/mo | Save substantially |
| Cosentyx (alt IL-17A) | ~$7,000/mo | Alt IL-17A biologic |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Siliq — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Siliq Prescription Program?
The Siliq Patient Assistance Program is free to apply. Our $69.95 per month covers full advocacy. Adalimumab biosimilars (Humira biosimilars) offer major cost savings for TNF-inhibitor pathway. REMS requirements for Siliq. Multiple biologic classes available for psoriasis — mechanism-based selection important.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Siliq assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Siliq is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Siliq:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $6,500–$8,500 per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Siliq assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Siliq Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Siliq:
Siliq is an anti-IL-17 receptor A monoclonal antibody — blocks IL-17RA subunit and multiple IL-17 family cytokines (IL-17A, IL-17F, IL-17A/F heterodimer, IL-17C, IL-17E). Broader IL-17 pathway blockade than IL-17A-specific biologics (Cosentyx, Taltz). REMS program due to suicidal ideation/behavior signal.
How It Works:
Plaque psoriasis is a chronic immune-mediated skin disease driven by IL-23/Th17 axis — IL-23 activates Th17 cells which produce IL-17 family cytokines that drive keratinocyte hyperproliferation and inflammatory infiltrate. Biologic therapy targeting this axis transformed psoriasis outcomes. IL-17 pathway biologics work at different levels: IL-17A-specific antibodies (Cosentyx/secukinumab, Taltz/ixekizumab) block only IL-17A. Bimekizumab (Bimzelx) blocks IL-17A + IL-17F. Brodalumab (Siliq) blocks IL-17RA subunit — blocks all IL-17 family cytokines signaling through IL-17RA (IL-17A, IL-17F, IL-17A/F, IL-17C, IL-17E) — broader downstream blockade. Similar clinical efficacy in psoriasis but with distinct pharmacology.
Form and Use:
Siliq 210 mg SC injection. Loading regimen: weeks 0, 1, 2 (210 mg each), then every 2 weeks maintenance. Self-administered at home after training. Cold storage.
Generic Availability:
No generic Siliq. Other IL-17 pathway biologics: Cosentyx (secukinumab — IL-17A monthly SC brand), Taltz (ixekizumab — IL-17A monthly SC brand), Bimzelx (bimekizumab — IL-17A + IL-17F every 8 weeks SC brand). IL-23 biologics: Tremfya (guselkumab), Skyrizi (risankizumab — every 12 weeks after loading), Ilumya (tildrakizumab), Stelara (ustekinumab — IL-12/23; and Selarsdi, Wezlana, others biosimilars). TNF inhibitors (extensive biosimilars): adalimumab (Humira and biosimilars — Amjevita, Yusimry, Cyltezo, Hulio, others; significantly cheaper than brand), etanercept (Enbrel and Erelzi, Eticovo biosimilars), infliximab (Remicade and Inflectra, Renflexis, Avsola biosimilars). Older systemics (all generic): methotrexate, cyclosporine, acitretin. Newer oral: Sotyktu (deucravacitinib — TYK2), Otezla (apremilast). National Psoriasis Foundation resources.
Warnings:
Suicidal ideation and behavior (BOXED WARNING — REMS program required; screen patients for depression/suicidal ideation before starting and monitor during; not for use in patients with active suicidal ideation or history of recent suicide attempt), serious infections (screen for TB before starting; assess infection status; avoid live vaccines), Crohn’s disease exacerbation (avoid in patients with inflammatory bowel disease), embryo-fetal considerations. Other: arthralgia, headache, fatigue, diarrhea, oropharyngeal pain, injection site reactions. Screen for TB. Vaccinate before starting. Mental health monitoring per REMS. Dermatology follow-up.
FAQ (Frequently Asked Questions)
How much does Siliq cost without insurance?
$6,500–$8,500 per month at specialty pharmacies. Adalimumab biosimilars (TNF-inhibitor psoriasis therapy) are significantly cheaper ($2,500–$4,000/month). IL-17A biologics (Cosentyx, Taltz) similar to Siliq pricing.
How is Siliq different from Cosentyx and Taltz?
All are IL-17 pathway biologics for psoriasis. Cosentyx (secukinumab) and Taltz (ixekizumab) are anti-IL-17A antibodies — block only IL-17A cytokine. Siliq (brodalumab) blocks IL-17 receptor A subunit — blocks signaling of multiple IL-17 family cytokines. Similar clinical efficacy in psoriasis but with distinct pharmacology. Siliq has REMS requirement for suicidal ideation risk.
What is REMS and why does Siliq require it?
Risk Evaluation and Mitigation Strategy — FDA safety program. Siliq REMS is due to suicidal ideation and behavior signal in early clinical development. REMS requires prescriber enrollment, patient education about risk, and monitoring for depression/suicidal ideation. Not for patients with active suicidal ideation or recent suicide attempt history.
How does Siliq compare to Humira (adalimumab)?
Different mechanisms and classes. Humira (adalimumab) is anti-TNF biologic — historically first-line psoriasis biologic, now with many biosimilars available (significantly cheaper). Siliq is anti-IL-17RA — different mechanism. Both effective for psoriasis. Choose based on prior therapy response, contraindications, and cost.
Can Siliq be used with methotrexate?
Discuss with dermatologist. Combining biologic with methotrexate may enhance efficacy but adds immunosuppression. Some patients on stable methotrexate add biologic; some on biologic monotherapy discontinue methotrexate. Individualized decision.
Take Control of Your Medication Costs
Biologic therapy transformed severe plaque psoriasis outcomes. Our advocacy team is ready — $69.95 per month, or free if we cannot help.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.